Fintel reports that on September 26, 2023, Cantor Fitzgerald reiterated coverage of Axogen (NASDAQ:AXGN) with a Overweight recommendation.
Analyst Price Forecast Suggests 226.92% Upside
As of August 31, 2023, the average one-year price target for Axogen is 15.30. The forecasts range from a low of 11.11 to a high of $21.00. The average price target represents an increase of 226.92% from its latest reported closing price of 4.68.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Axogen is 162MM, an increase of 9.71%. The projected annual non-GAAP EPS is -0.44.
What is the Fund Sentiment?
There are 283 funds or institutions reporting positions in Axogen. This is an increase of 1 owner(s) or 0.35% in the last quarter. Average portfolio weight of all funds dedicated to AXGN is 0.09%, a decrease of 1.63%. Total shares owned by institutions decreased in the last three months by 1.22% to 34,813K shares. 
The put/call ratio of AXGN is 0.05, indicating a bullish outlook.
What are Other Shareholders Doing?
ArrowMark Colorado Holdings holds 3,921K shares representing 9.12% ownership of the company. In it's prior filing, the firm reported owning 3,658K shares, representing an increase of 6.72%. The firm increased its portfolio allocation in AXGN by 0.03% over the last quarter.
First Light Asset Management holds 1,974K shares representing 4.59% ownership of the company. In it's prior filing, the firm reported owning 1,941K shares, representing an increase of 1.65%. The firm decreased its portfolio allocation in AXGN by 14.49% over the last quarter.
Bank Of America holds 1,803K shares representing 4.19% ownership of the company. In it's prior filing, the firm reported owning 1,776K shares, representing an increase of 1.51%. The firm increased its portfolio allocation in AXGN by 0.11% over the last quarter.
Soleus Capital Management holds 1,790K shares representing 4.16% ownership of the company. In it's prior filing, the firm reported owning 1,780K shares, representing an increase of 0.56%. The firm increased its portfolio allocation in AXGN by 4.30% over the last quarter.
William Blair Investment Management holds 1,611K shares representing 3.75% ownership of the company. In it's prior filing, the firm reported owning 1,589K shares, representing an increase of 1.41%. The firm decreased its portfolio allocation in AXGN by 9.81% over the last quarter.
Axogen Background Information
(This description is provided by the company.)
Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
